Related Experiment Video
Updated: Jul 9, 2026
19:15
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Prenatal methamphetamine use and neonatal neurobehavioral outcome
Lynne M Smith1, Linda L Lagasse, Chris Derauf
1Los Angeles Biomedical Institute at Harbor-UCLA Medical Center and David Geffen, School of Medicine at UCLA, Torrace, CA, USA. smith@labiomed.org
Neurotoxicology and Teratology
|November 23, 2007
Summary
Prenatal methamphetamine (MA) exposure impacts neonatal neurobehavior, causing decreased arousal and increased stress. Dose-response relationships suggest potential neurotoxic effects from MA.
Area of Science:
- Neonatal neurobehavioral research
- Developmental toxicology
- Maternal-fetal health
Background:
- Methamphetamine (MA) use during pregnancy is a growing concern in the US.
- The effects of prenatal MA exposure on neonatal neurobehavior are not well understood.
Purpose of the Study:
- To investigate the neurobehavioral outcomes in neonates exposed to MA prenatally.
- To determine the relationship between MA exposure levels and specific neurobehavioral patterns.
Main Methods:
- Longitudinal follow-up of 166 neonates (74 exposed) from the Infant Development, Environment and Lifestyle (IDEAL) study.
- Exposure assessed via meconium assay and self-report; alcohol, marijuana, and tobacco use were present in both groups.
- Neonatal neurobehavior evaluated using the NICU Network Neurobehavioral Scale (NNNS) within 5 days of birth.
Main Results:
- Prenatal MA exposure correlated with increased physiological stress in neonates.
- Heavy MA use was linked to reduced arousal, lethargy, and heightened stress.
- Trimester-specific MA use showed associations with stress abstinence (1st trimester) and poorer movement quality (3rd trimester).
- Higher amphetamine metabolite levels in meconium were associated with increased central nervous system (CNS) stress.
Conclusions:
- Prenatal MA exposure is linked to neurobehavioral deficits including decreased arousal, elevated stress, and impaired movement quality.
- Observed dose-response relationships suggest potential neurotoxic impacts of MA on neonatal development.
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...